These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19430002)

  • 1. Expanding the boundaries of clinical practice: building on experience with targeted therapies.
    Sternberg CN
    Ann Oncol; 2009 May; 20 Suppl 1():i1-6. PubMed ID: 19430002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
    Schöffski P; Bukowski R; Flodgren P; Ravaud A
    Ann Oncol; 2009 May; 20 Suppl 1():i25-i30. PubMed ID: 19430005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib for the treatment of metastatic renal cell carcinoma.
    Oudard S; Beuselinck B; Decoene J; Albers P
    Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib.
    Deeks ED; Keating GM
    Drugs; 2006; 66(17):2255-66; discussion 2267-8. PubMed ID: 17137406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in solid tumors.
    Gan HK; Seruga B; Knox JJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
    Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
    Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of gastrointestinal stromal tumours.
    Judson I; Demetri G
    Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib.
    Heng DY; Kollmannsberger C
    Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
    Khosravan R; Motzer RJ; Fumagalli E; Rini BI
    Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ; Escudier B; Gannon A; Figlin RA
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.